GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Price-to-Owner-Earnings

ValiRx (LSE:VAL) Price-to-Owner-Earnings : (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Price-to-Owner-Earnings?

As of today (2024-05-14), ValiRx's share price is £0.0305. ValiRx does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for ValiRx's Price-to-Owner-Earnings or its related term are showing as below:


LSE:VAL's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.165
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-14), ValiRx's share price is £0.0305. ValiRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.03. Therefore, ValiRx's PE Ratio for today is At Loss.

As of today (2024-05-14), ValiRx's share price is £0.0305. ValiRx's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.03. Therefore, ValiRx's PE Ratio without NRI for today is At Loss.

During the past 13 years, ValiRx's highest PE Ratio without NRI was 8.05. The lowest was 0.00. And the median was 6.25.


ValiRx Price-to-Owner-Earnings Historical Data

The historical data trend for ValiRx's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Price-to-Owner-Earnings Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ValiRx's Price-to-Owner-Earnings

For the Biotechnology subindustry, ValiRx's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ValiRx's Price-to-Owner-Earnings falls into.



ValiRx Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ValiRx's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0305/-0.03
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx  (LSE:VAL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ValiRx Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ValiRx's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Industry
Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.